DBV Technologies S.A. (DBVT) vs Nuvectis Pharma, Inc. (NVCT)
DBV Technologies S.A. and Nuvectis Pharma, Inc. are both Biotechnology companies. DBV Technologies S.A. and Nuvectis Pharma, Inc. are of similar size ($734.7M and $706.1M). Nuvectis Pharma, Inc. has the higher net margin (0.00% vs −3,564.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Nuvectis Pharma, Inc. leads on 6 and DBV Technologies S.A. on 5.
Valuation
Profitability
| Metric | DBVT | NVCT | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | — | 65.16% |
| Operating margin | (3,601.22%) | 0.00% | 0.00% |
| Net margin | (3,564.57%) | 0.00% | 0.00% |
| Free cash flow margin | (3,456.50%) | 0.00% | 0.00% |
| Return on equity | (142.63%) | (233.30%) | (57.72%) |
| Return on assets | (95.98%) | (122.61%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack